© 2023 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2023 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
John Mascarenhas, MD, reviews the case of a 76-year-old woman with myelofibrosis and her treatment with pacritinib.
April 20th 2022
John Mascarenhas, MD, presents the case of a 76-year-old woman with myelofibrosis and provides his initial impressions.
Dr John Mascarenhas explains the differences between myelofibrosis phenotypes and why it affects treatment regimen choices.
An expert describes the factors he considers when choosing a treatment for a patient with myelofibrosis, and how he judges treatment response.
Dr John Mascarenhas reviews the mechanism of action of pacritinib, a selective JAK2 inhibitor.
John Mascarenhas, MD, describes his personal experience with using pacritinib to treat patients with myelofibrosis and reviews the study design and outcomes for both the PERSIST-1 and PERSIST-2 trials.
Dr John Mascarenhas looks to the future of myelofibrosis treatment and shares some ongoing clinical trials and potential treatments that excite him.